Cristina Gamila Wakfie-Corieh

Prof. Cristina Gamila Wakfie-Corieh

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Domenico AlbanoDomenico Albano
Domenico Albano
ARAlessio Rizzo
Alessio Rizzo
Riemer H.J.A. SlartRiemer H.J.A. Slart
Riemer H.J.A. Slart
Søren HessSøren Hess
Søren Hess
Edel Noriega-ÁlvarezEdel Noriega-Álvarez
Edel Noriega-Álvarez
Giorgio TregliaGiorgio Treglia
Giorgio Treglia
The role of fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) is emerging for the assessment of non-oncological diseases, such as inflammatory and infectious diseases, even if the evidence in the literature is still in its initial phases. We conducted a systematic search of Scopus, PubMed/MEDLINE, Embase, and Cochrane library databases for studies published before 31 December 2023 reporting infectious and inflammatory disease imaging with FAPI PET/CT. We included twenty-one studies for a total of 1046 patients. The most frequent disease studied was lung interstitial disease, investigated in six studies for a total of 200 patients, followed by bone and joint diseases in two studies and 185 patients, IgG4-related disease in 53 patients, and Crohn’s disease in 30 patients. Despite the heterogeneity of studies in terms of study design and technical features, FAPI PET/CT showed a high detection rate and diagnostic role. Moreover, when compared with 2-[18F]FDG PET/CT (n = 7 studies), FAPI PET/CT seems to have better diagnostic performances. The presence of chronic inflammation and tissue remodeling, typical of immune-mediated inflammatory conditions, may be the underlying mechanism of FAPI uptake.

8 September 2020 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
CWCristina Gamila Wakfie-Corieh
Cristina Gamila Wakfie-Corieh
AGAlba María Blanes García
Alba María Blanes García
FFFederico Ferrando-Castagnetto
Federico Ferrando-Castagnetto
RVRaquel Valhondo-Rama
Raquel Valhondo-Rama
ACAida Ortega Candil
Aida Ortega Candil
JDJosé Luis Carreras Delgado
José Luis Carreras Delgado

4 June 2021 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
CWCristina Gamila Wakfie-Corieh
Cristina Gamila Wakfie-Corieh
FFFederico Ferrando-Castagnetto
Federico Ferrando-Castagnetto
AGAlba María Blanes García
Alba María Blanes García
MGMarta García García-Esquinas
Marta García García-Esquinas
ACAída Ortega Candil
Aída Ortega Candil
JDJosé Luis Carreras Delgado
José Luis Carreras Delgado
Although the novel coronavirus disease 2019 (COVID-19) can present as nonspecific clinical forms, subclinical cases represent an important route of transmission and a significant source of mortality, mainly in high-risk subpopulations such as cancer patients. A deeper knowledge of the metabolic shift in cells infected with severe acute respiratory syndrome coronavirus 2 could provide new insights about its pathogenic and host response and help to diagnose pulmonary involvement. We explored the potential added diagnostic value of 18F-FDG PET/CT scans in asymptomatic cancer patients with suspected COVID-19 pneumonia by investigating the association between metabolic and structural changes in the lung parenchyma. Methods: 18F-FDG PET/CT studies acquired between February 19 and May 29, 2020, were reviewed to identify those cancer patients with incidental findings suggestive of COVID-19 pneumonia. PET studies were interpreted through qualitative (visual) and semiquantitative (measurement of SUVmax) analysis evaluating lung findings. Several characteristic signs of COVID-19 pneumonia on CT were described as COVID-19 Reporting and Data System (CO-RADS) categories (1–6). After comparing the SUVmax of pulmonary infiltrates among different CO-RADS categories, we explored the best potential cutoffs for pulmonary SUVmax against CO-RADS categories as the gold standard result to eliminate the possibility that the diagnosis of COVID-19 pneumonia exists. Results: On multimodal PET/CT imaging, CT signs classified as CO-RADS category 5 or 6 were found in 16 of 41 (39%) oncologic patients. SUVmax was higher in patients with categories 5 and 6 than in patients with category 4 (6.17 ± 0.82 vs. 3.78 ± 0.50, P = 0.04) or categories 2 and 3 (3.59 ± 0.41, P = 0.01). A specificity of 93.8% (95% CI, 71.7%–99.7%) and an accuracy of 92.9% were obtained when combining a CO-RADS score of 5 or 6 with an SUVmax of 2.45 in pulmonary infiltrates. Conclusion: In asymptomatic cancer patients, the metabolic activity in lung infiltrates is closely associated with several combined tomographic changes characteristic of COVID-19 pneumonia. Multimodal 18F-FDG PET/CT imaging could provide additional information during early diagnosis in selected predisposed patients during the pandemic. The prognostic implications of simultaneous radiologic and molecular findings in cancer patients and other subpopulations at high risk for COVID-19 pneumonia deserve further evaluation in prospective research.

1 October 2020 in Radiology Case Reports
Verified
Journal Article
Open access
FFFederico Ferrando-Castagnetto
Federico Ferrando-Castagnetto
CWCristina Gamila Wakfie-Corieh
Cristina Gamila Wakfie-Corieh
AGAlba María Blanes García
Alba María Blanes García
MGMartha García García-Esquinas
Martha García García-Esquinas
RCRosa María Couto Caro
Rosa María Couto Caro
JDJosé Luis Carreras Delgado
José Luis Carreras Delgado
Cancer patients require a careful clinical follow-up during the coronavirus disease 2019 (COVID-19) pandemic. Although hybrid fluorine-18 Fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET/CT) is not routinely used in the management of COVID-19 patients, it could play a complementary role of other laboratory and radiological data in selected cases. We describe an asymptomatic cancer patient derived to 18F-FDGPET/CT with simultaneous findings of COVID-19 pneumonia and pulmonary thrombus, discussing its possible mechanisms and prognostic implications.

2 February 2019 in Revista Española de Medicina Nuclear e Imagen Molecular
Verified
Journal Article
Closed access
RVR. Valhondo-Rama
R. Valhondo-Rama
CWCristina Gamila Wakfie-Corieh
Cristina Gamila Wakfie-Corieh
EGE.A. Rodríguez Gallo
E.A. Rodríguez Gallo
MPM.J. Pérez-Castejón
M.J. Pérez-Castejón
JSJ.M. Brenes Sánchez
J.M. Brenes Sánchez
JCJ.L. Carreras-Delgado
J.L. Carreras-Delgado

5 February 2021 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
CWCristina Gamila Wakfie-Corieh
Cristina Gamila Wakfie-Corieh
CRCristina Rodríguez Rey
Cristina Rodríguez Rey
ACAida Ortega Candil
Aida Ortega Candil
FFFederico Ferrando-Castagnetto
Federico Ferrando-Castagnetto
RVRaquel Valhondo-Rama
Raquel Valhondo-Rama
JDJosé Luis Carreras Delgado
José Luis Carreras Delgado
Aim: We aimed to determine the frequency and clinical significance of breast incidental uptake (BIU) detected through fluorine-18 fluorodeoxyglucose (18F-FDG) PET/computed tomography (CT) in a single, high-load center. Patients and methods: In this retrospective study, we analyzed a total of 13 763 PET/CT studies performed from January 2017 to January 2020. After excluding 3148 scans, the maximum standardized uptake value (SUVmax) and maximum diameter (cm) of each BIU were measured. Clinical management, ultrasound/mammography and pathology reports were analyzed. Results: We found BIU in 27 scans of 26 patients (0.3% of the studies). Mean age was 62.2 years and 88.5% were women; 84.6% underwent PET/CT for oncological indications. Ultrasound/mammography was consequently performed in 23 patients (88.5%), and histological correlations were available for Breast Imaging Reporting and Data System categories 4 and 5. Finally, lesions were benign in 14 patients (60.9%; two of them with low/intermediate risk of malignancy) and malignant in nine patients (39.1%). The remaining three patients had no ultrasound/mammography reports. Mean SUVmax of benign and malignant lesions were 2.6 ± 1.4 and 5.8 ± 3.5, respectively (P = 0.002). Considering a SUVmax cut-off value of 4.0, the sensitivity and specificity for differentiating benign vs. malignant lesions were 67 and 93%, respectively. Benign lesions were smaller than malignant in CT (maximum diameter:1.3 ± 0.5 cm vs. 2.0 ± 1.0 cm, P = 0.02). Conclusion: Although BIU detected by 18F-FDG PET/CT is infrequently found, the risk of malignancy remains very high (39.1%). Both SUVmax and maximum diameter were greater in malignant than in benign lesions. An exhaustive study with ultrasound/mammography and selective histopathological correlation is mandatory after BIU findings, even in small lesions.